Healius Limited (AU:HLS)
ASX:HLS
Want to see AU:HLS full AI Analyst Report?
HLS Stock Chart & Stats
AU$0.54
-AU$0.02(-1.03%)
At close: 4:00 PM EST
AU$0.54
-AU$0.02(-1.03%)
Day’s Range― - ―
52-Week RangeAU$0.30 - AU$1.07
Previous CloseN/A
Volume575.57K
Average Volume (3M)2.94M
Market Cap
AU$228.74M
Enterprise ValueAU$1.86B
Total Cash (Recent Filing)AU$51.60M
Total Debt (Recent Filing)AU$1.66B
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Aug 09, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding726,155,800
10 Day Avg. Volume3,249,015
30 Day Avg. Volume2,941,962
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.26
Price to Sales (P/S)0.11
P/FCF Ratio0.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.44Price Target Upside-18.52% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering6
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$1.38B
Bulls Say, Bears Say
Bulls Say
Essential Fee-for-service DiagnosticsHealius' core fee-for-service model—pathology and imaging billed to government programs, insurers and patients—anchors demand to underlying healthcare utilization. This payment mix and referral-driven revenue provide structural stability and predictable cash flows over months, supporting recovery if volumes normalize.
Positive Operating Cash FlowSustained positive operating cash flow indicates the business can generate cash from core operations despite accounting losses. That cash provides liquidity to fund operations, service debt and invest in network efficiency, giving management more time to execute structural fixes without immediate financing stress.
Extensive Diagnostic Network And Referral LinksA broad footprint of labs, collection centres and imaging clinics creates scale advantages, entrenched referral relationships and fixed-cost absorption. This networked structure supports long-term volume capture, regional market share and operational leverage as utilization recovers or as management optimizes capacity.
Bears Say
Material Revenue DeclineA 13.8% revenue decline is a structural concern: lower volumes reduce fixed-cost absorption and limit margin recovery. If sustained, revenue erosion can force network rationalization, reduce bargaining power with payers and hinder reinvestment, extending the timeline to return to stable profitability.
Negative ProfitabilityA material negative net margin signals that core operations are not covering total costs. Persistent losses erode equity, constrain capital allocation and limit ability to fund growth or cope with reimbursement pressure. Turning margins positive is necessary for durable financial health and strategic flexibility.
High Leverage And Weak ReturnsElevated debt-to-equity and negative ROE increase financial vulnerability to lower volumes or policy shifts. High leverage raises interest and refinancing risk, reducing room for operational investments and making the company more sensitive to cash flow variability over the coming months.
Healius Limited News
HLS FAQ
What was Healius Limited’s price range in the past 12 months?
Healius Limited lowest share price was AU$0.30 and its highest was AU$1.07 in the past 12 months.
What is Healius Limited’s market cap?
Healius Limited’s market cap is AU$228.74M.
When is Healius Limited’s upcoming earnings report date?
Healius Limited’s upcoming earnings report date is Aug 09, 2026 which is in 60 days.
How were Healius Limited’s earnings last quarter?
Healius Limited released its earnings results on Feb 17, 2026. The company reported -AU$0.015 earnings per share for the quarter, missing the consensus estimate of -AU$0.001 by -AU$0.014.
Is Healius Limited overvalued?
According to Wall Street analysts Healius Limited’s price is currently Overvalued.
Does Healius Limited pay dividends?
Healius Limited pays a Notavailable dividend of AU$0.413 which represents an annual dividend yield of N/A. See more information on Healius Limited dividends here
What is Healius Limited’s EPS estimate?
Healius Limited’s EPS estimate is 0.02.
How many shares outstanding does Healius Limited have?
Healius Limited has 726,155,800 shares outstanding.
What happened to Healius Limited’s price movement after its last earnings report?
Healius Limited reported an EPS of -AU$0.015 in its last earnings report, missing expectations of -AU$0.001. Following the earnings report the stock price went down -6.748%.
Which hedge fund is a major shareholder of Healius Limited?
Currently, no hedge funds are holding shares in AU:HLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Healius Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
AU$0.44 (-18.52% Downside)
AU$0.44 (-18.52% Downside)
Blogger Sentiment
Bullish
AU:HLS Sentiment 93%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$92.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.24%
12-Months-Change
Fundamentals
Return on Equity
-29.48%
Trailing 12-Months
Asset Growth
-45.09%
Trailing 12-Months
Company Description
Healius Limited
Healius Limited is an Australian firm dedicated to delivering specialized diagnostic services to both individual consumers and healthcare practitioners. Its operations are structured into four primary segments: Pathology, Medical Imaging, Day Hospitals, and other miscellaneous services. The company's core offerings include comprehensive diagnostic imaging, private medical laboratory analysis, and various pathology services. Furthermore, under a diverse portfolio of brands such as Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs, alongside Lumus Imaging and Montserrat, Healius also facilitates a wide array of specialized surgical procedures. These encompass cataract removal, colonoscopies, gastroscopies, plastic and cosmetic operations, skin cancer excisions, IVF egg collection, and gynecological surgeries. The company boasts an extensive network across Australia, comprising 2,105 pathology facilities, 11 day hospitals, and 134 imaging centers. Established in 1994, the entity was originally known as Primary Health Care Limited, adopting the Healius Limited name in December 2018. Its corporate headquarters are situated in Sydney, Australia.
HLS Stock 12 Month Forecast
Average Price Target
AU$0.44
▼(-18.52% Downside)
Technical Analysis
Lumos Diagnostics Holdings Ltd.
―
Sonic Healthcare Limited
―
Integral Diagnostics Ltd.
―
Australian Clinical Labs Ltd
―
Monash IVF Group Ltd
―
Options Prices
Currently, No data available
---